Structure-activity relationships of 2-substituted phenyl-N-phenyl-2-oxoacetohydrazonoyl cyanides as novel antagonists of exchange proteins directly activated by cAMP (EPACs)

Zhiqing Liu, Yingmin Zhu, Haiying Chen, Pingyuan Wang, Fang C. Mei, Na Ye, Xiaodong Cheng, Jia Zhou

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Exchange proteins directly activated by cAMP (EPACs) are critical cAMP-dependent signaling pathway mediators that play important roles in cancer, diabetes, heart failure, inflammations, infections, neurological disorders and other human diseases. EPAC specific modulators are urgently needed to explore EPAC's physiological function, mechanism of action and therapeutic applications. On the basis of a previously identified EPAC specific inhibitor hit ESI-09, herein we have designed and synthesized a novel series of 2-substituted phenyl-N-phenyl-2-oxoacetohydrazonoyl cyanides as potent EPAC inhibitors. Compound 31 (ZL0524) has been discovered as the most potent EPAC inhibitor with IC50 values of 3.6 µM and 1.2 µM against EPAC1 and EPAC2, respectively. Molecular docking of 31 onto an active EPAC2 structure predicts that 31 occupies the hydrophobic pocket in cAMP binding domain (CBD) and also opens up new space leading to the solvent region. These findings provide inspirations for discovering next generation of EPAC inhibitors.

Original languageEnglish (US)
Pages (from-to)5163-5166
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume27
Issue number23
DOIs
StatePublished - Dec 1 2017

Fingerprint

Cyanides
Structure-Activity Relationship
Proteins
Medical problems
Nervous System Diseases
Modulators
Inhibitory Concentration 50
Heart Failure
Inflammation
Infection
Neoplasms

Keywords

  • Antagonist
  • EPAC
  • Exchange proteins directly activated by cAMP
  • Molecular docking

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Structure-activity relationships of 2-substituted phenyl-N-phenyl-2-oxoacetohydrazonoyl cyanides as novel antagonists of exchange proteins directly activated by cAMP (EPACs). / Liu, Zhiqing; Zhu, Yingmin; Chen, Haiying; Wang, Pingyuan; Mei, Fang C.; Ye, Na; Cheng, Xiaodong; Zhou, Jia.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 27, No. 23, 01.12.2017, p. 5163-5166.

Research output: Contribution to journalArticle

@article{d13d62ee17e04ca59e158c6b86cfdb17,
title = "Structure-activity relationships of 2-substituted phenyl-N-phenyl-2-oxoacetohydrazonoyl cyanides as novel antagonists of exchange proteins directly activated by cAMP (EPACs)",
abstract = "Exchange proteins directly activated by cAMP (EPACs) are critical cAMP-dependent signaling pathway mediators that play important roles in cancer, diabetes, heart failure, inflammations, infections, neurological disorders and other human diseases. EPAC specific modulators are urgently needed to explore EPAC's physiological function, mechanism of action and therapeutic applications. On the basis of a previously identified EPAC specific inhibitor hit ESI-09, herein we have designed and synthesized a novel series of 2-substituted phenyl-N-phenyl-2-oxoacetohydrazonoyl cyanides as potent EPAC inhibitors. Compound 31 (ZL0524) has been discovered as the most potent EPAC inhibitor with IC50 values of 3.6 µM and 1.2 µM against EPAC1 and EPAC2, respectively. Molecular docking of 31 onto an active EPAC2 structure predicts that 31 occupies the hydrophobic pocket in cAMP binding domain (CBD) and also opens up new space leading to the solvent region. These findings provide inspirations for discovering next generation of EPAC inhibitors.",
keywords = "Antagonist, EPAC, Exchange proteins directly activated by cAMP, Molecular docking",
author = "Zhiqing Liu and Yingmin Zhu and Haiying Chen and Pingyuan Wang and Mei, {Fang C.} and Na Ye and Xiaodong Cheng and Jia Zhou",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.bmcl.2017.10.056",
language = "English (US)",
volume = "27",
pages = "5163--5166",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "23",

}

TY - JOUR

T1 - Structure-activity relationships of 2-substituted phenyl-N-phenyl-2-oxoacetohydrazonoyl cyanides as novel antagonists of exchange proteins directly activated by cAMP (EPACs)

AU - Liu, Zhiqing

AU - Zhu, Yingmin

AU - Chen, Haiying

AU - Wang, Pingyuan

AU - Mei, Fang C.

AU - Ye, Na

AU - Cheng, Xiaodong

AU - Zhou, Jia

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Exchange proteins directly activated by cAMP (EPACs) are critical cAMP-dependent signaling pathway mediators that play important roles in cancer, diabetes, heart failure, inflammations, infections, neurological disorders and other human diseases. EPAC specific modulators are urgently needed to explore EPAC's physiological function, mechanism of action and therapeutic applications. On the basis of a previously identified EPAC specific inhibitor hit ESI-09, herein we have designed and synthesized a novel series of 2-substituted phenyl-N-phenyl-2-oxoacetohydrazonoyl cyanides as potent EPAC inhibitors. Compound 31 (ZL0524) has been discovered as the most potent EPAC inhibitor with IC50 values of 3.6 µM and 1.2 µM against EPAC1 and EPAC2, respectively. Molecular docking of 31 onto an active EPAC2 structure predicts that 31 occupies the hydrophobic pocket in cAMP binding domain (CBD) and also opens up new space leading to the solvent region. These findings provide inspirations for discovering next generation of EPAC inhibitors.

AB - Exchange proteins directly activated by cAMP (EPACs) are critical cAMP-dependent signaling pathway mediators that play important roles in cancer, diabetes, heart failure, inflammations, infections, neurological disorders and other human diseases. EPAC specific modulators are urgently needed to explore EPAC's physiological function, mechanism of action and therapeutic applications. On the basis of a previously identified EPAC specific inhibitor hit ESI-09, herein we have designed and synthesized a novel series of 2-substituted phenyl-N-phenyl-2-oxoacetohydrazonoyl cyanides as potent EPAC inhibitors. Compound 31 (ZL0524) has been discovered as the most potent EPAC inhibitor with IC50 values of 3.6 µM and 1.2 µM against EPAC1 and EPAC2, respectively. Molecular docking of 31 onto an active EPAC2 structure predicts that 31 occupies the hydrophobic pocket in cAMP binding domain (CBD) and also opens up new space leading to the solvent region. These findings provide inspirations for discovering next generation of EPAC inhibitors.

KW - Antagonist

KW - EPAC

KW - Exchange proteins directly activated by cAMP

KW - Molecular docking

UR - http://www.scopus.com/inward/record.url?scp=85033586796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033586796&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2017.10.056

DO - 10.1016/j.bmcl.2017.10.056

M3 - Article

VL - 27

SP - 5163

EP - 5166

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 23

ER -